PTCTNasdaqPharmaceutical PreparationsFiscal year ends December 31
PTC THERAPEUTICS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 30, 2026
$61.53+2.29 (+3.87%)
Close on Oct 19, 2026
- Market cap
- $5.66B
- P/E (TTM)
- –
- Dividend yield
- –
PTC THERAPEUTICS, INC. revenue by segment
By business segment
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net product revenue | $779.34M | $658.85M | $586.70M | $538.61M | $543.08M | $557.97M | $582.15M | $578.24M | $586.85M | $628.22M | $638.18M | $633.70M | 77.3% | +43.5% |
| Sephience | $387.01M | – | $111.15M | – | – | – | – | – | – | – | – | – | 38.4% | – |
| Royalty revenue | $268.12M | $254.62M | $244.22M | $223.00M | $213.57M | $209.15M | $203.86M | $196.70M | $185.51M | $169.18M | $168.86M | $157.73M | 26.6% | +25.5% |
| Emflaza | $108.33M | $120.05M | $146.36M | $169.80M | $186.58M | $197.52M | $207.22M | – | – | – | – | – | 10.7% | -41.9% |
| All other products | $36.29M | $37.42M | $37.26M | $34.56M | $35.92M | $39.29M | $36.95M | – | – | – | – | – | 3.6% | +1.0% |
| Manufacturing revenue | – | – | $0 | $0 | $0 | $301.00K | $1.66M | $2.63M | $5.00M | $7.06M | $7.69M | $6.72M | – | – |
| Collaboration revenue | – | – | – | – | – | – | – | – | – | – | $100.03M | $34.00K | – | – |
By region
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $456.74M | $340.91M | $252.19M | $191.06M | $186.58M | $197.52M | $207.22M | – | – | – | – | – | 45.3% | +144.8% |
| All other countries | $185.33M | $155.39M | $168.41M | $152.69M | $165.78M | $196.28M | $197.47M | – | – | – | – | – | 18.4% | +11.8% |
| Brazil | $82.00M | $74.54M | $65.66M | $40.63M | $60.63M | $72.88M | $72.08M | – | – | – | – | – | 8.1% | +35.3% |
| Russia | $55.27M | $88.01M | $100.45M | $154.23M | $130.09M | $91.29M | $105.38M | – | – | – | – | – | 5.5% | -57.5% |
From the segment and revenue-disaggregation notes of Ptc Therapeutics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.